We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients. The gene discussed is FOXM1; the disease is malignant peripheral nerve sheath tumor.